EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer

Jing Mao, Kai Wang

Clinical and Translational Medicine · 2026-07 · 16 (7)

DOI: 10.1002/ctm2.70699 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 08.07.2026. Verfasst von Jing Mao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary and Pancreatic Surgery Division, Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang Unive…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Oxidoreductases. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Nanchang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endoplasmic reticulum oxidoreductase 1α (ERO1A) is the core engine of oxidative protein folding in the endoplasmic reticulum (ER), playing a central role in maintaining ER redox homeostasis and modulating the unfolded protein response (UPR). Its aberrant overexpression in multiple solid tumors has established ERO1A as a critical regulator of tumor progression, microenvironment remodeling, and therapy resistance, positioning it as an emerging therapeutic target in precision oncology. Main body This review systematically synthesizes the structural biology, catalytic mechanisms, and regulatory networks of ERO1A, encompassing transcriptional control, post‐translational modifications, and compensatory alternative oxidases. We detail the multidimensional oncogenic functions of ERO1A, including intracellular promotion of proliferation, apoptosis resistance, migration, invasion, and epithelial‐mesenchymal transition, as well as extracellular remodeling of the tumor microenvironment via VEGF‐driven angiogenesis, PD‐L1‐mediated immune evasion, metabolic reprogramming, and induction of CD8 + T cell exhaustion and recruitment of immunosuppressive cells. The clinical relevance of ERO1A as an independent prognostic biomarker and its association with chemotherapy and immune checkpoint inhibitor resistance are critically evaluated. Current therapeutic strategies targeting ERO1A are classified into FAD‐competitive inhibitors, non‐competitive inhibitors, allosteric inhibitors, and emerging PROTAC degraders, with discussion of their mechanisms, selectivity, and translational hurdles.

Conclusion

ERO1A represents a promising yet challenging therapeutic node that connects ER stress adaptation with tumor pathogenesis. Overcoming the limitations of current inhibitors—particularly poor isoform selectivity, off‐target effects, and pharmacokinetic deficiencies‐through structure‐guided optimization, allosteric modulation, or protein degradation technologies will be essential for clinical translation. Future efforts should focus on biomarker‐driven patient stratification and rational combination with immunotherapies or conventional chemotherapies to maximize therapeutic benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentNeoplasmsOxidoreductasesHumansAnimalsMembrane Glycoproteins

Stichwörter der Autor:innen

ER stressERO1ATMEoxidative foldingtargeted therapy

Substanzen

ERO1A protein, humanOxidoreductasesMembrane Glycoproteins

Autor:innen und Institutionen

  • Hepatobiliary and Pancreatic Surgery Division, Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Ministry of Education, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Province Engineering Research Center of Hepatobiliary Disease, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Provincial Clinical Research Center for General Surgery Disease, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Förderung

  • National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Nanchang University

Zitieren

APA

Mao, J., & Wang, K. (2026). Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer. Clinical and Translational Medicine, 16(7). https://doi.org/10.1002/ctm2.70699

Vancouver

Mao J, Wang K. Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer. Clinical and Translational Medicine. 2026;16(7). doi:10.1002/ctm2.70699

BibTeX
@article{Mao2026,
  author = {Mao, Jing and Wang, Kai},
  title = {Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {7},
  doi = {10.1002/ctm2.70699}
}
Kostenlos starten →